Alexion Pharmaceuticals (ALXN)

Add to Watchlists
Create an Alert
190.29 +4.37  +2.35% NASDAQ Oct 24, 8:00PM BATS Real time Currency in USD

Alexion Pharmaceuticals Research and Development Expense (Quarterly):

100.66M for Sept. 30, 2014

View 4,000+ financial data types

View Full Chart

Alexion Pharmaceuticals Research and Development Expense (Quarterly) Chart

Export Data
Save Image

Alexion Pharmaceuticals Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1995. Start your Free Trial
Export Data Date Range:
Viewing of   First  Previous First  Previous   Next  Last Next   Last
Data for this Date Range  
Sept. 30, 2014 100.66M
June 30, 2014 92.55M
March 31, 2014 191.46M
Dec. 31, 2013 85.78M
Sept. 30, 2013 88.21M
June 30, 2013 68.56M
March 31, 2013 74.54M
Dec. 31, 2012 63.41M
Sept. 30, 2012 54.28M
June 30, 2012 59.64M
March 31, 2012 45.41M
Dec. 31, 2011 34.40M
Sept. 30, 2011 36.57M
June 30, 2011 35.65M
March 31, 2011 30.81M
Dec. 31, 2010 27.18M
Sept. 30, 2010 25.15M
June 30, 2010 23.69M
March 31, 2010 22.37M
Dec. 31, 2009 23.22M
Sept. 30, 2009 21.32M
June 30, 2009 18.29M
March 31, 2009 19.09M
Dec. 31, 2008 15.28M
Sept. 30, 2008 14.87M
   
June 30, 2008 16.82M
March 31, 2008 15.61M
Dec. 31, 2007 15.64M
Sept. 30, 2007 16.91M
June 30, 2007 15.20M
March 31, 2007 21.22M
Dec. 31, 2006 17.34M
Sept. 30, 2006 21.20M
June 30, 2006 23.46M
March 31, 2006 21.21M
Oct. 31, 2005 20.28M
July 31, 2005 10.08M
April 30, 2005 31.79M
Jan. 31, 2005 20.09M
Oct. 31, 2004 18.66M
July 31, 2004 17.84M
April 30, 2004 10.79M
Jan. 31, 2004 14.52M
Oct. 31, 2003 16.69M
July 31, 2003 18.59M
April 30, 2003 13.47M
Jan. 31, 2003 19.30M
Oct. 31, 2002 19.68M
July 31, 2002 19.38M
April 30, 2002 15.91M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More

Get data for
Advertisement

ALXN Research and Development Expense (Quarterly) Benchmarks

Companies
Gilead Sciences 583.92M
Vertex Pharmaceuticals 224.78M
Biogen Idec 417.17M

ALXN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 22.37M Mar 2010
Maximum 191.46M Mar 2014
Average 59.18M

ALXN Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("ALXN", "r_and_d_expense")
  • Last 5 data points: =YCS("ALXN", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts Professional.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.